Kamran Alam - 02 Jan 2024 Form 4 Insider Report for Taysha Gene Therapies, Inc. (TSHA)

Role: Chief Financial Officer
Signature: /s/ Kamran Alam
Issuer symbol: TSHA
Transactions as of: 02 Jan 2024
Net transactions value: $0
Form type: 4
Filing time: 04 Jan 2024, 16:43:04 UTC
Previous filing: 18 Dec 2023
Next filing: 06 Feb 2024
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	TSHA	Common Stock	Award	$0	+590,413	+234%	$0.000000	842,225	02 Jan 2024	Direct	F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	TSHA	Employee Stock Option (right to buy)	Award	$0	+590,413		$0.000000	590,413	02 Jan 2024	Common Stock	590,413	$1.71	Direct	F2

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Represents a restricted stock unit ("RSU") award. The RSUs will vest in four equal annual installments beginning on January 2, 2025, subject to the Reporting Person's continuous service through each applicable vesting date.
F2	25% of the total number of shares underlying the option shall vest and become exercisable on January 2, 2025 and the remainder shall vest and become exercisable in 36 equal monthly installments thereafter, subject to the Reporting Person's continuous service through each applicable vesting date.